252 related articles for article (PubMed ID: 36428480)
1. Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland.
Ślebioda TJ; Stanisławowski M; Kaszubowska L; Zaucha JM; Żmijewski MA
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428480
[TBL] [Abstract][Full Text] [Related]
2. Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update.
Petrou P
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):625-650. PubMed ID: 37288738
[TBL] [Abstract][Full Text] [Related]
3. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
Zinzi A; Gaio M; Liguori V; Cagnotta C; Paolino D; Paolisso G; Castaldo G; Nicoletti GF; Rossi F; Capuano A; Rafaniello C
Pharmacol Res; 2023 Apr; 190():106742. PubMed ID: 36963592
[TBL] [Abstract][Full Text] [Related]
4. Next-Generation Chimeric Antigen Receptor T-cells.
Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations.
Blüm P; Kayser S
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672680
[TBL] [Abstract][Full Text] [Related]
6. Impact of Manufacturing Procedures on CAR T Cell Functionality.
Watanabe N; Mo F; McKenna MK
Front Immunol; 2022; 13():876339. PubMed ID: 35493513
[TBL] [Abstract][Full Text] [Related]
7. The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
Ghanem B; Shi L
BioDrugs; 2022 Nov; 36(6):773-780. PubMed ID: 36167952
[TBL] [Abstract][Full Text] [Related]
8. Engineered T Cells: CAR T Cell Therapy and Beyond.
Johnson PC; Abramson JS
Curr Oncol Rep; 2022 Jan; 24(1):23-31. PubMed ID: 35059997
[TBL] [Abstract][Full Text] [Related]
9. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review.
Thavorn K; Thompson ER; Kumar S; Heiskanen A; Agarwal A; Atkins H; Shorr R; Hawrysh T; Chan KK; Presseau J; Ollendorf DA; Graham ID; Grimshaw JM; Lalu MM; Nochaiwong S; Fergusson DA; Hutton B; Coyle D; Kekre N
Value Health; 2024 Apr; ():. PubMed ID: 38641057
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.
Meng J; Wu X; Sun Z; Xun R; Liu M; Hu R; Huang J
Front Oncol; 2021; 11():698607. PubMed ID: 34381720
[TBL] [Abstract][Full Text] [Related]
11. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
[TBL] [Abstract][Full Text] [Related]
12. The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?
Knight E T; Oluwole O; Kitko C
Clin Hematol Int; 2024; 6(1):96-115. PubMed ID: 38817691
[TBL] [Abstract][Full Text] [Related]
13. Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T.
Crees ZD; Ghobadi A
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680329
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T cell: A cancer immunotherapy.
Singh S; Khasbage S; Kaur RJ; Sidhu JK; Bhandari B
Indian J Pharmacol; 2022; 54(3):226-233. PubMed ID: 35848695
[TBL] [Abstract][Full Text] [Related]
15. CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?
Fischer L; Grieb N; Platzbecker U; Vucinic V; Merz M
Eur J Haematol; 2024 Jan; 112(1):19-27. PubMed ID: 37547971
[TBL] [Abstract][Full Text] [Related]
16. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
Nakazawa Y
Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
[TBL] [Abstract][Full Text] [Related]
17. Current Progress in CAR-T Cell Therapy for Hematological Malignancies.
Han D; Xu Z; Zhuang Y; Ye Z; Qian Q
J Cancer; 2021; 12(2):326-334. PubMed ID: 33391429
[TBL] [Abstract][Full Text] [Related]
18. Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.
Meng J; Wu X; Sun Z; Xun R; Liu M; Hu R; Huang J
Front Oncol; 2021; 11():768128. PubMed ID: 34692553
[TBL] [Abstract][Full Text] [Related]
19. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL).
Chu Y; Lamb M; Cairo MS; Lee DA
Curr Treat Options Oncol; 2022 Mar; 23(3):381-403. PubMed ID: 35258793
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
